Square Pharmaceuticals PLC. (DSE: SQURPHARMA)

SQURPHARMA Income Statement

Financials in millions BDT. Fiscal year is July - June.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Revenue	68,811	62,748	57,598	50,703	45,876	44,034
Revenue Growth (YoY)	10.95%	8.94%	13.60%	10.52%	4.19%	11.05%
Cost of Revenue	35,598	32,582	28,719	25,470	23,141	22,635
Gross Profit	33,213	30,166	28,879	25,233	22,736	21,399
Selling, General & Admin	15,672	13,599	12,118	10,034	8,855	8,038
Other Operating Expenses	-119.61	-122.61	-98.27	-69.57	10.79	9.7
Operating Expenses	15,552	13,476	12,019	9,965	8,865	8,048
Operating Income	17,661	16,690	16,860	15,269	13,870	13,351
Interest Expense	-214.66	-118.97	-0.03	-0.01	-0.11	-0.08
Interest & Investment Income	4,301	3,773	3,004	3,137	2,965	2,037
Earnings From Equity Investments	2,584	2,523	2,011	1,291	586.24	931.71
Currency Exchange Gain (Loss)	68.94	650.1	451.34	19.42	-0.7	37.31
Other Non Operating Income (Expenses)	-0	-0	-	34.43	33.62	82.8
EBT Excluding Unusual Items	24,400	23,516	22,325	19,751	17,455	16,439
Gain (Loss) on Sale of Investments	81.97	184.69	384.59	177.04	100.09	134.77
Gain (Loss) on Sale of Assets	-79.8	-79.8	53.49	-	28.38	18.69
Other Unusual Items	0.62	0.62	0.72	32.06	-	-
Pretax Income	24,403	23,622	22,764	19,960	17,583	16,593
Income Tax Expense	4,163	4,642	4,607	4,013	4,229	3,940
Earnings From Continuing Operations	20,240	18,980	18,157	15,947	13,354	12,652
Minority Interest in Earnings	-1.92	-0.24	0.03	-	-	-6.68
Net Income	20,238	18,980	18,157	15,947	13,354	12,646
Net Income to Common	20,238	18,980	18,157	15,947	13,354	12,646
Net Income Growth	7.33%	4.53%	13.86%	19.42%	5.60%	9.07%
Shares Outstanding (Basic)	886	886	886	886	886	886
Shares Outstanding (Diluted)	886	886	886	886	886	886
Shares Change (YoY)	-	-	-	-	-0.00%	-0.00%
EPS (Basic)	22.83	21.41	20.48	17.99	15.06	14.27
EPS (Diluted)	22.83	21.41	20.48	17.99	15.06	14.27
EPS Growth	7.33%	4.53%	13.86%	19.42%	5.60%	9.07%
Free Cash Flow	10,339	5,721	6,692	7,178	8,718	10,343
Free Cash Flow Per Share	11.66	6.45	7.55	8.10	9.83	11.67
Dividend Per Share	10.500	10.500	10.000	6.000	4.476	3.738
Dividend Growth	5.00%	5.00%	66.67%	34.04%	19.74%	24.83%
Gross Margin	48.27%	48.08%	50.14%	49.77%	49.56%	48.60%
Operating Margin	25.67%	26.60%	29.27%	30.11%	30.23%	30.32%
Profit Margin	29.41%	30.25%	31.52%	31.45%	29.11%	28.72%
Free Cash Flow Margin	15.03%	9.12%	11.62%	14.16%	19.00%	23.49%
EBITDA	20,462	19,000	18,695	17,151	15,791	15,365
EBITDA Margin	29.74%	30.28%	32.46%	33.83%	34.42%	34.89%
D&A For EBITDA	2,801	2,310	1,835	1,882	1,921	2,014
EBIT	17,661	16,690	16,860	15,269	13,870	13,351
EBIT Margin	25.67%	26.60%	29.27%	30.11%	30.23%	30.32%
Effective Tax Rate	17.06%	19.65%	20.24%	20.10%	24.05%	23.75%
Revenue as Reported	68,811	62,748	57,598	50,703	45,876	44,034
Advertising Expenses	-	4.96	3.61	3.01	8.7	6.12

Source: S&P Capital IQ. Standard template. Financial Sources.